Possible relationship between esophageal dilatation and severity of \textit{M. abscessus} pulmonary disease

Hiromichi Hara*, Keitaro Okuda*, Jun Araya, Hirofumi Utsumi, Daisuke Takekoshi, Saburo Ito, Hiroshi Wakui, Shunsuke Minagawa, Takanori Numata, Kazuyoshi Kuwano

Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
*A: These authors contributed equally to this work. hirohara@jikei.ac.jp

Abstract

Objectives
Recently, incidence of \textit{Mycobacterium abscessus (Mab)} pulmonary disease (Mab-PD) is increasing worldwide. We aimed to identify factors associated with severity of \textit{Mycobacterium abscessus (Mab)} pulmonary disease (Mab-PD).

Methods
All patients diagnosed as Mab-PD based on the official ATS/IDSA statement between 2017 January 1 and 2021 July 31 were included (n = 13). We reviewed medical records, bacteriological and laboratory data of the patients. Severity of lung lesions and esophageal diameters in chest CT were quantitatively evaluated. Gaffky score in the sputum was used as airway mycobacterial burden. We explored the factors associated with high CT score and high Gaffky score.

Results
Maximum diameter of esophagus (MDE) in severe disease (CT score $\geq$ 10) was greater than that in milder disease (CT score <10) (18.0±7.9mm, 9.3±3.1mm, respectively, p = 0.01), and MDE was well correlated with CT score (R = 0.69, p = 0.007). MDE in high mycobacterial burden group (Gaffky score $\geq$ 5) tended to be greater than that in low mycobacterial burden group (Gaffky score <5) (16.1±6.8mm, 10.1±5.5mm, respectively, p = 0.12), and MDE was well correlated with Gaffky score (R = 0.68, p = 0.009). Lung lesions were bilateral and predominant in middle or lower lobes.

Conclusions
Esophageal dilatation was correlated with severity of Mab-PD and airway mycobacterial burden. Gastroesophageal reflux might be associated with Mab disease progression.
Introduction

*Mycobacterium abscessus* (Mab) is one of rapidly growing non-tuberculous mycobacteria (NTM) [1]. *Mab* comprises three subspecies (*M. abscessus subsp. abscessus, M. abscessus subsp. massiliense and M. abscessus subsp. bolletii*), which affects both airway and lung parenchyma [2,3]. In comparison to *M. avium complex* (MAC), *Mab* is less commonly isolated from respiratory specimens [4], hence clinical characteristics of *Mycobacterium abscessus* (Mab) pulmonary disease (Mab-PD) remains to be elucidated.

Recently, incidence of Mab-PD is increasing worldwide including Japan [4,5]. Indeed, the incidence rate for Mab-PD increased from 0.1 cases in 2001 to 0.5 cases per 100000 person-years in 2014 in Japan [5]. Mab-PD often results in poor clinical outcome due to broad drug resistance of the mycobacteria [6,7]. Thus, Mab-PD is becoming an important public health problem, and there is an urgent need for elucidating clinical characteristics and the risk factors for Mab-PD exacerbation to diagnose in early stage and prevent progression of the disease.

A variety of comorbidities (bronchiectasis, obstructive lung diseases including asthma and COPD, malignancies, rheumatoid arthritis, gastroesophageal reflux and so on) and conditions (steroid use, inhaled corticosteroid use, low body weight) were considered to be associated with pulmonary infection of NTM [4,8–13]. Those underlying clinical conditions might be associated with not only increased incidence of NTM-PD but also progression of the disease. However, reported papers do not precisely evaluate the association between underlying clinical conditions and disease severity of Mab-PD. In this study, we investigated characteristics of Mab-PD patients and attempted to identify the factors associated with disease severity and airway mycobacterial burden.

Methods

Study subjects

This study is a retrospective cohort study of patients diagnosed as Mab-PD based on the official ATS/IDSA statement at Jikei University Hospital from January 1, 2017 (01/01/2017) to July 31, 2021 (07/31/2021). Patients were eligible for the study if they met the following inclusion criteria 1) Age ≥ 20 years old, 2) patients diagnosed as Mab-PD based on the official ATS/IDSA statement [1].

A total of 13 patients were included in this study. This study was approved by the Ethics Committee of Jikei University (33–219 (10836)), and adhered to the tenet of medical ethics. Based on the ethical guidelines of Jikei University, informed consent was not necessary for this retrospective study, and we performed opt-out consent on the website of our hospital. All data were fully anonymized after we collected data from medical records. All data was anonymized prior to statistical analysis. There are ethical restrictions on sharing de-identified data set since the data contain potentially identifying or sensitive patient information. Data from this study are available upon request (Hiromichi Hara, E-mail: hirohara@jikei.ac.jp or ethics committee of Jikei University, E-mail: crb@jikei.ac.jp). Patients’ medical records during 2017 (01/01/2017) to July 31, 2021 (07/31/2021) were accessed. Chest computed tomography (CT) was performed when obtained respiratory samples proved to be culture-positive for Mab. The chest CT findings of these patients were evaluated by two specialists of the Japanese Respiratory Society (H.H. and O.K.).

Diagnosis of Mab-PD

Respiratory samples from patients with clinical suspicion of NTM pulmonary disease were cultured on Ogawa media, and species of cultured mycobacteria were determined by mass
Diagnosis of Mab-PD was made based on the official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases [1].

Data collection
We retrospectively reviewed the medical records of the enrolled patients. Clinical characteristics including age, sex, BMI, smoking history, comorbidities, underlying lung disease, symptoms of increased sputum, and Gaffky score in sputum were investigated. Maximum number of Gaffky score was recorded. CT score was calculated based on a scoring system for MAB-PD in a previous report [14]. A total score of 30 was allocated for five types of lung lesions including bronchiectasis (9 points), bronchiolitis (6 points), cavity (9 points), nodule (3 points), and consolidation (3 points) depending on severity of lung lesions. Maximum diameter of esophagus (MDE) was measured on axial Chest CT images (5mm slice), and the longest distance of the esophageal air was measured without touching the wall as reported in a prior study [15]. We defined radiologically severe disease as CT score $\geq 10$ and milder disease as CT score $<10$. We also defined bacteriologically severe group as Gaffky score $\geq 5$ and milder disease as Gaffky score $<5$. MDE $\geq 15$mm was considered Esophageal dilatation [16] according to the previous report.

Statistical analysis
Student’s t-tests, or Fisher’s exact tests were performed to compare clinical indices of radiologically severe disease (CT score $\geq 10$) and milder disease (CT score $<10$). Clinical indices of bacteriologically severe group (Gaffky score $\geq 5$) and milder disease (Gaffky score $<5$)were also compared. Regression analysis were performed to estimate the relationship between MDE and CT score, MDE and Gaffky scale. A two-sided $p<0.05$ was considered statistically significant. All statistical analyses were performed with StatView, version 5 (SAS Institute Inc., Cary, NC, USA).

Results
Clinical characteristics of Mab-PD (Table 1)
Characteristics of Mab-PD patients (n = 13) were shown in Table 1. Four patients (30.8%) had obstructive lung disease, and 3 patients (23.1%) used ICS. Six patients out of 12 patients (50%) were positive anti-GPL-core IgA antibody, and sputum culture of 3 patients (23.1%) were positive for other NTM or for aspergillus.

Comparison of clinical characteristics of patients with severe disease and milder disease (Table 2)
According to previous paper, severity of lung disease was scored by means of CT evaluation [14]. Mab-PD patients were divided into two groups according to the severity of the lung disease (CTscore $\geq 10$, and CT score $<10$). Maximum diameter of esophagus (MDE) in severe disease (CTscore $\geq 10$) was greater than that in milder disease (CT score $<10$) (18.0±7.9mm, 9.3±3.1mm, respectively, $p = 0.01$). Maximum number of Gaffky score in severe disease (CT score $\geq 10$) tended to be greater than that in milder disease (5.5±3.3, 2.8±2.2, respectively, $p = 0.1$). MDE was well correlated with CT score ($R = 0.69$, $p = 0.007$, Fig 1A).
Distribution and CT pattern of parenchymal abnormality in Mab-PD

(Table 3)

Distribution and CT pattern of parenchymal abnormality in Mab-PD were shown in Table 3. Bilateral bronchiectasis and bronchiolitis in middle or lower lobes were predominant. Cavity and nodules were rare in this study.

Clinical characteristics of patients with high mycobacterial burden in sputum (Table 4)

Clinical characteristics of patients with high mycobacterial burden in sputum was shown in Table 4. Obstructive lung disease and use of inhaled steroid, well-known risk factors for NTM were associated with high mycobacterial burden. MDE in high mycobacterial burden group (Gaffky score $\geq 5$) tended to be greater than that in the low mycobacterial burden group (Gaffky score $<5$) (15.0±5.8mm, 9.8±5.3mm, respectively, $p = 0.03$), and MDE was well correlated with Gaffky score ($R = 0.68$, $p = 0.009$ Fig 1B). We showed CT scans of typical cases of esophageal dilatation in Fig 2, and those of normal esophageal diameter in Fig 3.

Discussion

In this study, we demonstrated that (1) Maximum diameter of esophagus (MDE) in radiologically severe disease (CT score $\geq 10$) was greater than that in milder disease (CT score $<10$) and MDE was well correlated with CT score. (2) MDE in high mycobacterial burden group (Gaffky

| Table 1. Clinical characteristics of all patients (n = 13). |
|---------------------------------------------------------|
| Total (n = 13)                                           |
| Age (years) 61.4±16.5                                   |
| Male (%) 4 (30.8)                                       |
| BMI 19.5±3.2                                            |
| History of smoking (%) 4 (30.8)                         |
| malignancy (%) 3 (23.1)                                |
| GERD (%) 4 (30.8)                                      |
| Autoimmune diseases (%) 2 (15.4)                       |
| Use of steroid or immunosuppressant (%) 4 (30.8)       |
| Obstructive lung diseases (%) 4 (30.8)                 |
| Use of inhaled corticosteroid (%) 3 (23.1)             |
| increased sputum 8 (61.5)                              |
| Maximum number of Gaffky scale 3.6±2.8                 |
| Gaffky scale $\geq 5$ (%) 4 (30.8)                      |
| CT score 7.4±3.4                                       |
| Maximum diameter of esophagus(mm) 12.0±6.3             |
| Alb(g/dl) 3.9±0.4                                      |
| CRP(mg/dl) 1.4±2.6                                     |
| positive anti-GPL-core IgA antibody 6(50)              |
| unknown n = 1                                          |
| positive culture of other NTM in sputum 3 (23.1)       |
| positive culture of other aspergillus in sputum 3 (23.1)|

BMI: Body Mass Index.
GERD: Gastroesophageal Reflux Disease.
NTM: Non-tuberculous mycobacteria.

https://doi.org/10.1371/journal.pone.0261866.t001
Table 2. Comparison of clinical characteristics of patients with severe disease and milder disease.

|                        | CT score ≥ 10 (n = 4) | CT score < 10 (n = 9) | p value |
|------------------------|------------------------|-----------------------|---------|
| Age (years)            | 68.5±8.2               | 58.2±18.6             | 0.32    |
| Male (%)               | 2 (50)                 | 2 (22.2)              | 0.53    |
| BMI                    | 17.4±3.7               | 20.5±2.6              | 0.11    |
| History of smoking (%) | 1 (25)                 | 3 (33.3)              | >0.99   |
| Malignancy (%)         | 1 (25)                 | 2 (22.2)              | >0.99   |
| GERD (%)               | 2 (50)                 | 2 (22.2)              | 0.53    |
| Autoimmune diseases(%) | 0 (0)                  | 2 (22.2)              | >0.99   |
| Use of steroid or immunosuppressant (%) | 1 (25) | 3 (33.3) | >0.99 |
| Obstructive lung diseases (%) | 2 (50) | 2 (22.2) | 0.53 |
| Use of inhaled corticosteroid (%) | 1 (25) | 2 (22.2) | >0.99 |
| Increased sputum       | 1 (25)                 | 7 (77.8)              | 0.22    |
| Maximum number of Gaffky scale | 5.5±3.3 | 2.8±2.2 | 0.1    |
| Gaffky scale ≥ 5 (%)   | 2 (50)                 | 2 (22.2)              | 0.53    |
| CT score               | 10.8±1.5               | 6.67±2.3              | 0.008   |
| Maximum diameter of esophagus (mm) | 18.0±7.9 | 9.29±3.1 | 0.01 |
| Alb(g/dl)              | 4.0±0.5                | 3.9±0.4               | 0.83    |
| CRP(mg/dl)             | 1.4±2.6                | 1.4±2.8               | 0.99    |
| Positive anti-GPL-core IgA antibody | 2 (50) | 4 (50) | >0.99 |
| Positive culture of other NTM in sputum | unknown n = 1 | | |
| Positive culture of other aspergillus in sputum | 1 (25) | 2 (22.2) | >0.99 |

BMI: Body Mass Index.
GERD: Gastroesophageal Reflux Disease.
NTM: Non-tuberculous mycobacteria.

https://doi.org/10.1371/journal.pone.0261866.t002

Fig 1. Correlation of CT score (A), Gaffky score (B) and maximum diameter of esophagus (MDE) Correlation of CT score and maximum diameter of esophagus (MDE) is shown in A. Correlation of Gaffky score and MDE is shown in B.

https://doi.org/10.1371/journal.pone.0261866.g001
score $\geq 5$) tended to be greater than that in low mycobacterial burden group (Gaffky score <5), and MDE was well correlated with Gaffky score. Accordingly, esophageal dilatation can be associated with severity of Mab-PD and airway mycobacterial burden. It is also likely that gastroesophageal reflux might be associated with Mab disease progression.

Gastroesophageal reflux disease (GERD) is one of the well-known risk factors for NTM-PD [17]. Since NTM can survive in acid conditions, GERD followed by aspiration of refluxed gastric contents containing NTM is one of considerable mechanisms of NTM-PD [18]. Since significant relationship between the presence of GERD and esophageal dilatation (ED) in the CT scan was shown in a previous study [19], we measured diameters of esophagus to detect subclinical or undiagnosed GERD. Both radiological and bacteriological disease severities were significantly correlated with MDE in this study, suggesting that subclinical GERD is highly associated with pathogenesis of Mab progression of pulmonary disease. In consistent with our results, Koh et.al

| CT pattern   | CT score(average) | Unilateral | Bilateral | Right lung | Left lung | total (Max 78) |
|--------------|-------------------|------------|-----------|------------|-----------|----------------|
| Bronchiectasis | 2.5              | 1          | 9         | 4          | 10        | 6              | 1              | 7              | 7              | 35               |
| Bronchiolitis  | 2.9              | 1          | 10        | 4          | 8         | 9              | 1              | 8              | 8              | 38               |
| Cavity        | 0.8              | 1          | 1         | 0          | 0         | 1              | 0              | 0              | 2              | 3               |
| Nodules       | 0.3              | 4          | 0         | 1          | 0         | 2              | 2              | 0              | 0              | 1               |
| Consolidation | 0.9              | 3          | 6         | 2          | 4         | 7              | 2              | 3              | 4              | 22               |

https://doi.org/10.1371/journal.pone.0261866.t003

Table 4. Clinical characteristics of patients with high bacterial burden in sputum.

|                         | Gaffky$\geq 5$ (n = 4) | Gaffky$<5$ (n = 9) | p value |
|-------------------------|------------------------|--------------------|---------|
| Age (years)             | 56.8±16.7              | 63.4±16.9          | 0.52    |
| Male (%)                | 3 (75)                 | 1 (11.1)           | 0.05    |
| BMI                     | 20.9±4.5               | 18.9±2.5           | 0.32    |
| History of smoking (%)  | 0 (0)                  | 4 (44.4)           | 0.23    |
| Malignancy (%)          | 1 (25)                 | 2 (22.2)           | $>0.99$ |
| GERD (%)                | 2 (50)                 | 2 (22.2)           | 0.53    |
| Autoimmune diseases(%)  | 0 (0)                  | 2 (22.2)           | $>0.99$ |
| Use of steroid or immunosuppressant(%) | 1 (25) | 3(33.3) | $>0.99$ |
| Obstructive lung diseases(%) | 4 (100) | 0 (0) | 0.001 |
| Use of inhaled corticosteroid(%) | 3 (75) | 0 (0) | 0.01 |
| increased sputum        | 3 (75)                 | 5(55.6)            | $>0.99$ |
| Maximum number of Gaffky scale | 6.5±2.4 | 2.3±1.8 | 0.005 |
| CT score                | 9.0±3.4                | 7.4±2.6            | 0.38    |
| Maximum diameter of esophagus(mm) | 16.1±6.8 | 10.1±5.5 | 0.12 |
| Alb(g/dl)               | 3.8±0.48               | 4.0±0.44           | 0.49    |
| CRP(mg/dl)              | 1.9±2.5                | 1.2±2.8            | 0.68    |
| positive anti-GPL-core IgA antibody | 2(50) | 4 (50) | $>0.99$ |
| positive culture of other NTM in sputum | 1 (25) | 2 (22.2) | $>0.99$ |
| positive culture of other aspergillus in sputum | 2(50) | 1 (11.1) | 0.2 |

BMI;Body Mass Index.
GERD;Gastroesophageal Reflux Disease.
NTM;Non-tuberculous mycobacteria.

https://doi.org/10.1371/journal.pone.0261866.t004
Fig 2. Typical cases of esophageal dilatation. CT images of three cases whose maximum diameter of esophagus is larger than 15mm were shown.

https://doi.org/10.1371/journal.pone.0261866.g002

Fig 3. Typical cases of normal esophageal diameter. CT images of three cases whose maximum diameter of esophagus is less than 10 mm were shown.

https://doi.org/10.1371/journal.pone.0261866.g003
previously reported that NTM patients with GERD were more likely to have a positive sputum smear for acid-fast bacilli and were affected more lobes than patients without GERD [17]. Involvement of Mab-PD lesions were bilateral and predominant in middle or lower lobes in the present study, which may reflect the participation of GERD-associated aspiration in progression of lung lesions. Since CT is routinely performed to evaluate lung lesions of Mab-PD in almost all patients in Japan, MDE might be a useful tool to detect subclinical GERD without additional invasive procedure. In patients with increased MDE, improving intestinal motility, and Semi-Fowler’s positioning during night might have some effect to attenuate disease progression of Mab-PD by preventing aspiration of swallowed mycobacteria or contaminated water or food.

This study has several limitations. Firstly, due to low prevalence of Mab infection, the sample size was small. We could not perform multivariate analysis. Confounding factors might influence the results of this study. However, esophageal dilatation evaluated by MDE showed strongest association with disease severity among known risk factors for NTM in monovariate analysis. Although larger studies are necessary to confirm our results, MDE could be a useful and simple biomarker for Mab-PD exacerbation. Secondly, patients’ population of this study might be different from patients in previous reports. While patients classified as upper lobe cavitary form were included in other studies, there were no such patients in this study. Upper lobe cavitary form may not to be associated with GERD, suggesting that risk factors for Mab-PD can be different in those patients. Finally, we did not determine subspecies of Mab and clinical characteristics can be different among the subspecies. Although previous studies demonstrated that CT findings of M massiliense disease overlap with those of M abscessus disease, further studies are needed to precisely evaluate the difference among Mab subspecies.

Conclusions
Esophageal dilatation was associated with severity and airway mycobacterial burden of Mab infection. It is likely that unaware gastroesophageal reflux can be causally linked to Mab disease progression.

Author Contributions
Conceptualization: Hiromichi Hara, Jun Araya, Daisuke Takekoshi.
Data curation: Hiromichi Hara, Keitaro Okuda, Hirofumi Utsumi, Daisuke Takekoshi, Saburo Ito, Hiroshi Wakui, Shunsuke Minagawa, Takanori Numata, Kazuyoshi Kuwano.
Formal analysis: Hiromichi Hara, Keitaro Okuda.
Funding acquisition: Hiromichi Hara.
Investigation: Hiromichi Hara.
Methodology: Hiromichi Hara.
Resources: Hiromichi Hara.
Software: Hiromichi Hara.
Validation: Hiromichi Hara.
Visualization: Hiromichi Hara.
Writing – original draft: Hiromichi Hara.
Writing – review & editing: Hiromichi Hara, Keitaro Okuda, Jun Araya, Hirofumi Utsumi, Daisuke Takekoshi, Kazuyoshi Kuwano.
References

1. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESC MID/IDSA clinical practice guideline. Eur Respir J 2020; 56.

2. Victoria L, Gupta A, Gómez JL, et al. Mycobacterium abscessus complex: A Review of Recent Developments in an Emerging Pathogen. Front Cell Infect Microbiol 2021; 11:659997. https://doi.org/10.3389/fcimb.2021.659997 PMID: 33981630

3. Johansen MD, Herrmann JL, Kremer L. Nontuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol 2020; 18:392–407. https://doi.org/10.1038/s41579-020-0331-1 PMID: 32086501

4. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015; 36:13–34. https://doi.org/10.1016/j.ccm.2014.10.002 PMID: 25676516

5. Namkung H, Kurashima A, Morimoto K, et al. Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis 2016; 22:1116–1117. https://doi.org/10.3201/eid2206.151086 PMID: 27191735

6. Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180:896–902. https://doi.org/10.1164/rccm.200905-0704OC PMID: 19661243

7. Flight WG, Hough NE, Chapman SJ. Outcomes of pulmonary Mycobacterium abscessus infection. Int J Mycobacteriol 2020; 9:48–52. https://doi.org/10.4103/ijmy.ijmy_3_20 PMID: 32474488

8. Tung YJ, Bittaye SO, Tsai JR, et al. Risk factors for microbiologic failure among Taiwanese adults with Mycobacterium abscessus complex pulmonary disease. J Microbiol Immunol Infect 2015; 48:437–445. https://doi.org/10.1016/j.jmii.2014.08.005 PMID: 25440976

9. Uno S, Asakura T, Morimoto K, et al. Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis. BMC Pulm Med 2020; 20:262. https://doi.org/10.1186/s12890-020-01304-6 PMID: 33036598

10. Lee AR, Lee J, Choi SM, et al. Phenotypic, immunologic, and clinical characteristics of patients with nontuberculous mycobacterial lung disease in Korea. BMC Infect Dis 2013; 14:558. https://doi.org/10.1186/1471-2334-13-558 PMID: 24274658

11. Andréjak C, Nielsen R, Thomsen V, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013; 68:256–262. https://doi.org/10.1136/thoraxjnl-2012-201772 PMID: 22781123

12. Liu VX, Winthrop KL, Lu Y, et al. Association between Inhaled Corticosteroid Use and Pulmonary Nontuberculous Mycobacterial Infection. Ann Am Thorac Soc 2018; 15:1169–1176. https://doi.org/10.1513/AnnalsATS.201804-245OC PMID: 30213194

13. Szturnowicz M, Oniszk Z, Wrońska-Wiór, et al. Non-Tuberculous Mycobacteria in Respiratory Specimens of Patients with Obstructive Lung Diseases-Colonization or Disease? Antibiotics (Basel) 2020; 9.

14. Kim HS, Lee KS, Koh WJ, et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 2012; 263:260–270. https://doi.org/10.1148/radiol.12111374 PMID: 22371609

15. Takekoshi D, Arami S, Sheppard TJ, et al. Computed Tomography of the Esophagus in Scleroderma and Lung Disease. Tohoku J Exp Med 2015; 237:345–352. https://doi.org/10.1620/tjem.237.345 PMID: 26639310

16. Schraufnagel DE, Michel JC, Sheppard TJ, et al. CT of the normal esophagus to define the normal air column and its extent and distribution. AJR Am J Roentgenol 2008; 191:748–752. https://doi.org/10.2214/AJR.07.3455 PMID: 18716104

17. Koh WJ, Lee JH, Kwon YS, et al. Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease. Chest 2007; 131:1825–1830. https://doi.org/10.1378/chest.06-2280 PMID: 17400660

18. Dawns SN, Kautz M, Chan ED, et al. Mycobacterium abscessus and Gastroesophageal Reflux: An In Vitro Study. Am J Respir Crit Care Med 2020; 202:466–469. https://doi.org/10.1164/rcrm.202001-0011LE PMID: 32298605

19. Hashemi SJ, Javad Moosavi SA, Idani E, et al. Association of esophageal dilatation with gastroesophageal reflux disease: A case control study. Monaldi Arch Chest Dis 2018; 88:914. https://doi.org/10.4081/monaldi.2018.914 PMID: 29962193